Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 3
1996 6
1997 7
1998 7
1999 7
2000 17
2001 19
2002 22
2003 29
2004 26
2005 29
2006 37
2007 36
2008 51
2009 27
2010 26
2011 41
2012 53
2013 56
2014 48
2015 49
2016 58
2017 55
2018 43
2019 55
2020 49
2021 62
2022 64
2023 47
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

940 results

Results by year

Filters applied: . Clear all
Page 1
The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Wang W, Lu Z, Wang M, Liu Z, Wu B, Yang C, Huan H, Gong P. Wang W, et al. Front Immunol. 2022 Aug 30;13:998236. doi: 10.3389/fimmu.2022.998236. eCollection 2022. Front Immunol. 2022. PMID: 36110851 Free PMC article.
SubMap analysis revealed patients with high-CuproptosisScore may respond to anti-PD-1 therapy. The IC50 values of Bexarotene, Bicalutamide, Bortezomib, and Cytarabine were lower in the high-CuproptosisScore group than those in the low-CuproptosisScore group. ...
SubMap analysis revealed patients with high-CuproptosisScore may respond to anti-PD-1 therapy. The IC50 values of Bexarotene, Bicalut …
Bexarotene.
Lowe MN, Plosker GL. Lowe MN, et al. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2. doi: 10.2165/00128071-200001040-00006. Am J Clin Dermatol. 2000. PMID: 11702369 Review.
An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL. ...At clinically relevant oral dosages, bexarotene significantly decreases levels of serum thyrotropin and free thyroxine. ...
An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL. ...At …
The novel function of bexarotene for neurological diseases.
Liu Y, Wang P, Jin G, Shi P, Zhao Y, Guo J, Yin Y, Shao Q, Li P, Yang P. Liu Y, et al. Ageing Res Rev. 2023 Sep;90:102021. doi: 10.1016/j.arr.2023.102021. Epub 2023 Jul 24. Ageing Res Rev. 2023. PMID: 37495118 Review.
Bexarotene, a retinoid X receptor (RXR) agonist, is approved by FDA to treat cutaneous T-cell lymphoma. ...Here, we briefly discuss the characteristics, applications, and adverse effects of bexarotene, summarize its pharmacological mechanisms and therapeutic results …
Bexarotene, a retinoid X receptor (RXR) agonist, is approved by FDA to treat cutaneous T-cell lymphoma. ...Here, we briefly discuss t …
Potential therapeutic uses of rexinoids.
Leal AS, Reich LA, Moerland JA, Zhang D, Liby KT. Leal AS, et al. Adv Pharmacol. 2021;91:141-183. doi: 10.1016/bs.apha.2021.01.004. Epub 2021 Mar 4. Adv Pharmacol. 2021. PMID: 34099107 Review.
Genetic models using deletion or overexpression of RXR and the subsequent development of several small molecules that are agonists or antagonists of this receptor support a promising therapeutic role for these receptors in immunology. Bexarotene was approved in 1999 for th …
Genetic models using deletion or overexpression of RXR and the subsequent development of several small molecules that are agonists or antago …
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D, Savage KJ, Lilley C, Lisano J, Liu J, Yu KS. Elsea D, et al. Adv Ther. 2023 May;40(5):2326-2338. doi: 10.1007/s12325-023-02470-9. Epub 2023 Mar 15. Adv Ther. 2023. PMID: 36920744 Free PMC article.
INTRODUCTION: Brentuximab vedotin versus physician's choice of methotrexate (MTX) or bexarotene (BEX) significantly improved progression-free survival (PFS) (median PFS, 16.7 vs. 3.5 months) and delayed time to subsequent treatment (8.4 vs. 3.7 months), with similar overal …
INTRODUCTION: Brentuximab vedotin versus physician's choice of methotrexate (MTX) or bexarotene (BEX) significantly improved progress …
Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis.
Kobayashi T, Mitsuhashi A, Hongying P, Shioya M, Kojima K, Nishikimi K, Yahiro K, Shozu M. Kobayashi T, et al. Sci Rep. 2022 Jul 1;12(1):11123. doi: 10.1038/s41598-022-15348-7. Sci Rep. 2022. PMID: 35778597 Free PMC article.
Bexarotene reduced cell proliferation in all concentrations in both the cells. ...Thus, bexarotene may serve as a novel therapeutic agent for ovarian cancer....
Bexarotene reduced cell proliferation in all concentrations in both the cells. ...Thus, bexarotene may serve as a novel therap …
Bexarotene: a clinical review.
Farol LT, Hymes KB. Farol LT, et al. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. doi: 10.1586/14737140.4.2.180. Expert Rev Anticancer Ther. 2004. PMID: 15056048 Review.
Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. ...Subsequent Phase II/III trials have demonstrated a greater than 50% response rate …
Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor …
Impact of body mass index on the severity of bexarotene-associated hypertriglyceridemia: A post hoc analysis of an open-labeled clinical study of combined bexarotene and phototherapy in Japanese patients with cutaneous T-cell lymphoma.
Sanagawa A, Hayakawa T, Nishida E, Yamamoto A, Ikumi K, Mori Y, Hotta Y, Kimura K, Furukawa-Hibi Y, Morita A. Sanagawa A, et al. J Dermatol. 2023 Jul;50(7):917-926. doi: 10.1111/1346-8138.16801. Epub 2023 Apr 11. J Dermatol. 2023. PMID: 37041679
In particular, hypertriglyceridemia often requires a reduction or even suspension of bexarotene therapy. The risk factors of bexarotene-associated severe hypertriglyceridemia are not clear. ...Further studies for optimizing the initial bexarotene dose in such …
In particular, hypertriglyceridemia often requires a reduction or even suspension of bexarotene therapy. The risk factors of bexar …
Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R, Thompson A, Gangar P, Duvic M. Talpur R, et al. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. doi: 10.1016/j.clml.2014.01.010. Epub 2014 Feb 4. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24589156
During a second phase I/II dose-ranging combination trial, participants were treated with pralatrexate at 15 mg/m(2)/wk for 3 of 4 weeks combined with 150 to 300 mg/m(2) of daily oral bexarotene. RESULTS: Twenty-six patients were enrolled at our center, including 12 receiv …
During a second phase I/II dose-ranging combination trial, participants were treated with pralatrexate at 15 mg/m(2)/wk for 3 of 4 weeks com …
940 results